Cadrenal Therapeutics reported net income of -$3.32M for the quarter ended Jun 2026. This income statement covers 18 quarters of results from Mar 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating items | ||||||||||||||||||
| Depreciation & Amortization - TotalDep. & Amort. (Tot) | 506.00 | 760.00 | 190.00 | 597.00 | 597.00 | 597.00 | 597.00 | 470.00 | 407.00 | 401.00 | 504.00 | |||||||
| Research & DevelopmentR&D | 0.02M | 0.20M | 0.06M | 0.12M | 3.24M | 0.24M | 0.24M | 0.36M | 0.63M | 1.25M | 0.78M | 1.08M | 0.71M | |||||
| Selling, General & AdministrativeSG&A | 0.15M | 0.28M | 0.92M | 0.96M | 0.96M | 0.78M | 0.90M | 0.90M | 1.13M | 1.21M | 1.67M | 2.66M | 2.63M | |||||
| Operating ExpensesOpex | 0.17M | 0.48M | 0.97M | 1.08M | 4.20M | 1.03M | 1.14M | 1.26M | 1.76M | 2.47M | 2.46M | 3.73M | 3.34M | |||||
| Operating IncomeOp. Inc | -0.17M | -0.48M | -0.97M | -1.08M | -4.20M | -1.03M | -1.14M | -1.26M | -1.76M | -2.47M | -2.46M | -3.73M | -3.34M | |||||
| EBIT | -0.17M | -0.48M | -0.97M | -1.08M | -4.20M | -1.03M | -1.14M | -1.26M | -1.76M | -2.47M | -2.46M | -3.73M | -3.34M | |||||
| Non-operating items | ||||||||||||||||||
| Non Operating Interest Expenses | 0.01M | 0.01M | 0.01M | 3.99M | 0.97M | -0.97M | ||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 3.00 | 1.00 | 0.02M | 0.11M | 0.12M | 0.09M | 0.07M | 0.05M | 0.07M | 0.02M | ||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.74M | |||||||||||||||||
| Non Operating IncomeNon Op. Inc. | -0.02M | -0.05M | -3.93M | -0.97M | 0.02M | 0.11M | 0.12M | 0.09M | 0.07M | 0.05M | 0.07M | 0.02M | ||||||
| Net income details | ||||||||||||||||||
| EBT | -0.18M | -0.49M | -0.99M | -5.07M | -5.17M | -0.03M | -1.04M | -1.14M | -1.66M | -2.39M | -2.41M | -3.67M | -3.32M | |||||
| Profit After TaxPAT | -0.18M | -0.50M | -1.03M | -5.01M | -5.17M | -1.00M | -1.04M | -1.14M | -1.66M | -2.39M | -2.41M | -3.67M | -3.32M | |||||
| Income from Continuing OperationsIncome (Continuing) | -0.18M | -0.49M | -0.99M | -5.07M | -5.17M | -0.03M | -1.04M | -1.14M | -1.66M | -2.39M | -2.41M | -3.67M | -3.32M | |||||
| Consolidated Net IncomeConsol Net Inc. | -0.18M | -0.49M | -0.99M | -5.07M | -5.17M | -0.03M | -1.04M | -1.14M | -1.66M | -2.39M | -2.41M | -3.67M | -3.32M | |||||
| Income towards Parent CompanyParent Net Inc | -0.18M | -0.49M | -0.99M | -5.07M | -5.17M | -0.03M | -1.04M | -1.14M | -1.66M | -2.39M | -2.41M | -3.67M | -3.32M | |||||
| Net Income towards Common StockholdersNet Income | -0.18M | -0.49M | -0.99M | -5.07M | -5.17M | -0.03M | -1.04M | -1.14M | -1.66M | -2.39M | -2.41M | -3.67M | -3.32M | |||||
| Additional items | ||||||||||||||||||
| EPS (Basic) | -0.35 | -0.95 | -1.84 | -9.63 | -7.20 | -0.04 | -1.01 | -1.27 | -1.56 | -2.24 | -2.18 | -1.87 | -1.14 | |||||
| EPS (Diluted) | -0.35 | -0.95 | -1.84 | -9.63 | -7.20 | -0.04 | -1.01 | -1.27 | -1.56 | -2.24 | -2.18 | -1.87 | -1.14 | |||||
| Shares Outstanding | 0.50M | 0.51M | 0.54M | 0.53M | 0.72M | 0.78M | 1.03M | 0.90M | 1.07M | 1.07M | 1.10M | 1.22M | 1.84M | 1.96M | 2.04M | 1.99M | 2.41M | 2.91M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.50M | 0.51M | 0.54M | 0.53M | 0.72M | 0.78M | 1.03M | 0.90M | 1.07M | 1.07M | 1.10M | 1.22M | 1.84M | 1.96M | 2.04M | 1.99M | 2.41M | 2.91M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.50M | 0.53M | 0.54M | 0.55M | 0.78M | 0.78M | 0.87M | 0.87M | 1.07M | 1.07M | 1.23M | 1.22M | 1.91M | 2.01M | 2.06M | 2.34M | 2.51M | 3.10M |
| EBITDA | -0.17M | -0.48M | -0.97M | -1.08M | -4.20M | -1.03M | -1.14M | -1.26M | -1.76M | -2.47M | -2.46M | -3.73M | -3.34M | |||||
| Interest ExpensesInt Expense | 0.01M | 0.01M | 0.01M | 3.99M | 0.97M | -0.97M |